SEC Comment Letter 0000000000-23-002810 to Tharimmune, Inc. (THAR) (CIK 0001861657) (THAR)
Tharimmune, Inc. (THAR) (CIK 0001861657)
Date: March 21, 2023 · CIK: 0001861657 · Accession: 0000000000-23-002810
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-270684
Letter
United States securities and exchange commission logo March 21, 2023 Randy Milby Chief Executive Officer Hillstream BioPharma Inc. 1200 Route 22 East, Suite 2000 Bridgewater, NJ 08807 Re:Hillstream BioPharma Inc. Registration Statement on Form S-3 Filed March 17, 2023 File No. 333-270684 Dear Randy Milby: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Arzhang Navai at 202-551-4676 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Nazia J. Khan
Show Raw Text
United States securities and exchange commission logo
March 21, 2023
Randy Milby
Chief Executive Officer
Hillstream BioPharma Inc.
1200 Route 22 East, Suite 2000
Bridgewater, NJ 08807
Re:Hillstream BioPharma Inc.
Registration Statement on Form S-3
Filed March 17, 2023
File No. 333-270684
Dear Randy Milby:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Arzhang Navai at 202-551-4676 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Nazia J. Khan